

# FRESH THINKING AND THE NEWEST ADVANCES START HERE

## PROGRAM HIGHLIGHTS

This seminar series focuses on key challenges of the prevention, treatment and patient management approaches associated with viral hepatitis, advancing cirrhosis, liver cancer and fatty liver disease.

- ▶ Updated content based on the latest medical guidelines and clinical trial results
- ▶ Strong patient-focused educational sessions employing evidence-based studies from the latest AASLD, EASL and DDW programs
- ▶ Local experts at each program provide an interdisciplinary, team approach to patient care
- ▶ A highly interactive format that stresses improved patient outcomes
- ▶ BONUS SESSION on SARS-CoV-2 and Liver Disease
- ▶ Participants can receive up to **10.0 AMA PRA Category 1 Credits™** or up to **12 nursing education** credits

## WHO SHOULD ATTEND?

This program was developed for Gastroenterologists, Internists, Hepatologists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

## THE BENEFITS OF PARTICIPATION

- ▶ Acquire countless practice 'pearls' from the nation's top liver disease specialists
- ▶ Gain new insight on the cutting edge approaches to optimize clinical outcomes for your patients
- ▶ Participate with local colleagues to solve real-world clinical cases
- ▶ Utilize the clinical resources and referral opportunities found in your community



For more information or to register for either the live or enduring material, please go to: <https://bit.ly/hepandCLD22> for more details.



FEBRUARY 26

Pasadena, CA

Hilton Pasadena

**Tse-Ling Fong, MD**  
USC Keck School of Medicine

**Sammy Saab, MD, MPH**  
UCLA Geffen School of Medicine

**Lucy Mathew ACNP-BC**  
Cedars Sinai Medical Center



MARCH 19

Raleigh, NC

Embassy Suites-Crabtree

**Andrew Muir, MD**  
Duke University School of Medicine

**Sydney Barritt, IV, MD**  
University of North Carolina Medical School

**Elizabeth Goacher, PA-C**  
Duke University Hospital



APRIL 30

Denver, CO

The Curtis Hotel

**Lisa Forman, MD**  
University of Colorado Health

**Avash Kalra, MD**  
University of Colorado Health

**Micheal Ball, PharmD**  
Presbyterian/St. Luke's Medical Center

## FUTURE EVENTS:



MARCH 5

Louisville, KY

Univ. of Louisville, Clinical & Translational Research Bldg.

**Craig McClain, MD** **Ashutosh Barve, MD, PhD**  
University of Louisville School of Medicine University of Louisville School of Medicine

**Barbara Cave, PhD, APRN** **Matthew Cave, MD**  
University of Louisville Hospital University of Louisville School of Medicine

**Loretta Jophlin, MD**  
University of Louisville School of Medicine



APRIL 2

Houston, TX

Hilton Houston Plaza-Medical Center

**Victor Machicao, MD**  
University of Texas Health Science Center

**Saira Khaderi, MD, MPH**  
Baylor University School of Medicine

Additional Faculty to be Added



ENDURING MATERIAL

Web-based Activity




A self-paced, Web-based learning activity that has all the content of the live event and a faculty of national experts. Engage in the seminar at a convenient time and place.

May 14: Irvine, CA  
June 4: Richmond, VA  
October 8: San Diego, CA

Non-Profit Org.  
U.S. Postage  
Paid  
Louisville, Ky.  
Permit No. 769

UNIVERSITY OF  
**LOUISVILLE**  
Continuing Medical Education &  
Professional Development  
University of Louisville  
Louisville, KY 40292


PREVENTION & THERAPIES FOR  
HEPATITIS AND  
CHRONIC LIVER  
DISEASE



Available as a live, in person seminar or a web-based learning activity.

B1

# PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE



## NEW FOR THE 2022 SEMINAR SERIES

- ▶ Updated COVID-19 Precautions for the health and safety of our participants
- ▶ How Alcohol and Alcohol Abuse is Increasing Liver Disease
- ▶ Treating Chronic Liver Disease in Special Populations
- ▶ SARS-CoV2 and the Long-term Effect on Liver Health
- ▶ New content, lectures and case studies reflecting the current advances in diagnosis, treatment and patient care
- ▶ A hybrid delivery platform that utilizes live, F-2-F presentations and/or web-based lectures to optimize learning and time efficiency

UL CONTINUING MEDICAL EDUCATION & PROFESSIONAL DEVELOPMENT

SC Liver Research Consortium

# ENHANCE YOUR Knowledge | Competence | Confidence

## SEMINAR OVERVIEW

This seminar series provides up-to-date presentations on the diagnosis and treatment of the dominant forms of viral hepatitis and explore the latest on advancing liver disease, hepatocellular carcinoma, fatty liver disease and other hepatic conditions.

Location-specific faculty experts will deliver their material utilizing a curriculum that features timely lectures, case analysis, clinical trial outcomes and progress reports on promising prevention approaches and emerging therapies.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment, and care management approaches in a setting that stresses interactive learning, audience participation, and collaborative discussion.

Available in both a live seminar or a web-based enduring material, the program will increase the number of clinicians educated in preventing, diagnosing, treating, and/or referring liver-disease patients for more advanced care. The goal of this CME activity is to limit future cases and improve the outcomes of those already infected.

### New for the 2022 Seminar Series:

- ▶ Fresh clinical cases to test your knowledge of both **clinical theory and actual practice**.
- ▶ New Modules on:
  - **SARS-CoV-2 and Liver Disease**
  - **Elimination approaches to Hepatitis B**
  - **Alcoholic liver disease and Alcoholic Hepatitis**
  - **Treating liver disease in special populations**
- ▶ Implementation of the **current CDC-recommended COVID safety and sanitation precautions** at all live seminars. We request that all participants be vaccinated.
- ▶ Increased program flexibility allows you to participate in a live, **F-2-F seminar** or an **ABIM/MOC approved, web-based activity**. Both are eligible for Category I CME credits.™

## WHY SHOULD YOU PARTICIPATE?

- ▶ **UPDATE** your clinical knowledge with expert faculty and internationally recognized studies
- ▶ **VALIDATE** your clinical decision processes and patient care approaches
- ▶ **COLLABORATE** with local colleagues to discuss new diagnostic and treatment options

## PROGRAM TOPICS

Seminar content is delivered as a live seminar supplemented by a few recorded presentations.

- ▶ Opening Comments and Pre-Test
- ▶ Hepatitis C: Update on Diagnostics and Treatment
- ▶ Clinical Case Analysis
- ▶ Hepatitis B: Epidemiology, Natural History and Testing
- ▶ Delta Hepatitis and Hepatitis E Update
- ▶ The growing relationship between HBV and Delta Hepatitis
- ▶ Elimination of Hepatitis B
- ▶ Product Theaters and Networking Opportunities
- ▶ Anti-viral Therapies for HBV
- ▶ End Stage Liver Disease, Cirrhosis and Live Transplant
- ▶ Hepatocellular Carcinoma: Screening and disease management approaches
- ▶ Hepatocellular Carcinoma: New Systemic Treatment Options
- ▶ SARS-CoV-2 and Liver Disease
- ▶ Promising Therapies for Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC)
- ▶ Alcoholic Liver Disease
- ▶ Epidemiology, Demographics and Diagnosis of Fatty Liver Disease
- ▶ NASH Treatments in Practice and in Development
- ▶ Overcoming the Barriers to Liver Health in Special Populations
- ▶ Closing Comments and Post Test

## COURSE DIRECTORS

### Paul Pockros, MD, FAASLD, FAGG

Director, Liver Disease Center  
Scripps Clinic

Director, SC Liver Research Consortium

### Catherine Frenette, MD, FAST

Co-Director, SC Liver Research Consortium

## EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- ▶ Review the history, epidemiology, demographics, natural history, immunology, and pathophysiology that leads to increased incidence of viral hepatitis.
- ▶ Explain the factors that have led to a resurgence of Hepatitis A and the diagnostic and treatment guidelines for Delta Hepatitis and Hepatitis E.
- ▶ Review the current therapies for PBC and clinical approaches for PSC.
- ▶ Incorporate new and emerging treatment regimens for PBC from the latest EASL and AASLD presented papers.
- ▶ Summarize the causes of chronic liver disease and hepatic encephalopathy and promising treatments.
- ▶ Explore the causes and impact of alcohol on liver wellbeing and progressive liver disease.
- ▶ Perform the appropriate diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma (HCC).
- ▶ Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
- ▶ Discover the pathway and barriers to liver disease elimination and the unique challenges of special populations.
- ▶ Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management.
- ▶ Improve the health of patients infected with hepatitis virus, liver cancer and other progressive liver diseases.

## REGISTRATION INFORMATION

	Enduring Material	Live Seminar Early Registration	Live Seminar Regular Registration
Physicians, Clinical Pharmacists and Administrators	\$95	\$135	\$150
Nurses, Nurse Practitioners and PA's	\$70	\$85	\$95
Medical Residents & Fellows	\$50	\$70	\$80

**To Register & For More Information:** <https://bit.ly/hepandCLD22>

*Or call: SC Liver Research Consortium at (253) 432-4023*

**Early Registration** ends Wednesday prior to program date.

**Regular Registration** begins Thursday prior to program date.

**Cancellation Policy:** Requests for cancellation must be submitted to [cmepd@louisville.edu](mailto:cmepd@louisville.edu) at least seven (7) days prior to the program. Such requests will receive a full refund less a \$20 processing fee.

## ACCREDITATION

### Joint Provider Statement



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

## DESIGNATION STATEMENT

**Physicians (MD/DO)** - The University of Louisville School of Medicine designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners & Physician Assistants** - AANP and AAPA accept Category I credit from **AMA PRA Category 1 Credit(s)™** organizations accredited by ACCME.

## SPONSORS



The mission of the **University of Louisville** Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit <http://louisville.edu/medicine/cme>



The **SC Liver Research Consortium (SCLRC)** is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC's mission is to

team research sponsors and SCLRC's over 90 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. For more information visit [www.scliver.com](http://www.scliver.com)

## DISCLOSURE

### Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

### Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.